| | 956104-40-8 Basic information More.. |
| Product Name: | Apalutamide | | Synonyms: | ARN-509;AR509;AR509 100G;ARV-509;ARN-509;ARN 509; ARN509;4-(7-(4-Cyano-3-(trifluoromethyl)phenyl)-8-hydroxy-6-thioxo-5,7-diazaspiro[3.4]octan-5-yl)-2-f;AR509/AR-509;ARN | | CAS: | 956104-40-8 | | MF: | C21H15F4N5O2S | | MW: | 477.43 | | EINECS: | 807-449-9 | | Mol File: | 956104-40-8.mol |  |
Use
ARN-509 (10 mg/kg/d, oral) inhibits tumor growth with decreased proliferative index and increased apoptotic rate in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dose dependently inhibits tumor growth with highest efficacy at dose of 30 mg/kg/day in castrate male immunodeficient mice harboring LNCaP/AR-luc xenograft tumors. ARN-509 dosed at 10 mg/kg/d for 28 days results in a 3-fold reduction in prostates weight associated with lacking glandular secretory activity and 1.7-fold reduction in epididymis weight in adult male dogs. ARN-509 (10 mg/kg/d, oral) inhibits cell proliferation of prostate tissues in adult male dogs. ARN-509 is safe and well tolerated in 24 patients with metastatic CRPC who has progressed on prior treatments and peak plasma concentrations occurred 2 to 3 hours after administration. ARN-509 results in durable PSA declines at doses ranging from 30 to 300 mg in patients with metastatic CRPC. ARN-509 shows powerful anti-cancer activity and induces durable remissions long after therapy completion in castrate resistant prostate cancer mouse models.
- ARN-509
-
- US $1.00 / g
- 2024-07-12
- CAS:956104-40-8
- Min. Order: 1g
- Purity: 99%
- Supply Ability: 100kg
- Apalutamide
-
- US $0.00 / Kg/Bag
- 2024-07-10
- CAS:956104-40-8
- Min. Order: 2Kg/Bag
- Purity: 0.99
- Supply Ability: 20 tons
- Apalutamide
-
- US $0.00 / Kg/Bag
- 2024-07-10
- CAS:956104-40-8
- Min. Order: 2Kg/Bag
- Purity: 0.99
- Supply Ability: 20 tons
|
|
956104-40-8
Recommend Suppliers |
|